Exact Sciences Corp (EXAS): D Scott Coward , SVP and General Counsel of Exact Sciences Corp sold 1,644 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $12.28 per share for a total value of $20,188.32 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 4, 2016, D Scott Coward (SVP and General Counsel) sold 1,685 shares at $6.62 per share price.On Mar 11, 2016, Maneesh Arora (COO) sold 4,042 shares at $6.05 per share price.Also, On Mar 11, 2016, Graham Peter Lidgard (Chief Science Officer) sold 3,041 shares at $6.05 per share price.On Mar 11, 2016, Kevin T Conroy (President and CEO) sold 6,895 shares at $5.81 per share price.
EXACT Sciences Corporation: On Friday, Jul 1, 2016 heightened volatility was witnessed in EXACT Sciences Corporation which led to swings in the share price. The shares opened for trading at $12.29 and hit $12.4899 on the upside , eventually ending the session at $12.31, with a gain of 0.49% or 0.06 points. The heightened volatility saw the trading volume jump to 51,19,029 shares. The 52-week high of the share price is $29.9999 and the company has a market cap of $1,204 M . The 52-week low of the share price is at $4.67.
Company has been under the radar of several Street Analysts.EXACT Sciences Corporation is Upgraded by Craig Hallum to Buy and the brokerage firm has set the Price Target at $18. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Jun 16, 2016.EXACT Sciences Corporation is Downgraded by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 6.50 from a previous price target of $12 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 4, 2016.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.